Cencora, Inc.

BOVESPA:C1CO34 Stock Report

Market Cap: R$271.5b

Cencora Past Earnings Performance

Past criteria checks 1/6

Cencora has been growing earnings at an average annual rate of 30.7%, while the Healthcare industry saw earnings growing at 21.6% annually. Revenues have been growing at an average rate of 10.2% per year. Cencora's return on equity is 193.1%, and it has net margins of 0.5%.

Key information

30.7%

Earnings growth rate

31.2%

EPS growth rate

Healthcare Industry Growth11.6%
Revenue growth rate10.2%
Return on equity193.1%
Net Margin0.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Cencora makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BOVESPA:C1CO34 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24293,9591,5095,6610
30 Jun 24283,8311,8565,5650
31 Mar 24276,5371,8525,4860
31 Dec 23271,5791,8675,4180
30 Sep 23262,1731,7455,3100
30 Jun 23254,4251,6895,1800
31 Mar 23247,5431,6175,0880
31 Dec 22241,8051,7294,9700
30 Sep 22238,5871,6994,8490
30 Jun 22236,3251,8424,8010
31 Mar 22229,6661,7274,5020
31 Dec 21221,1011,6144,0290
30 Sep 21213,9891,5403,5940
30 Jun 21204,321-3,7443,0620
31 Mar 21196,282-3,7472,8150
31 Dec 20194,546-3,2222,7790
30 Sep 20189,894-3,4092,7670
30 Jun 20186,2871,5702,7680
31 Mar 20186,1591,5822,7580
31 Dec 19182,0616492,6930
30 Sep 19179,5898552,6640
30 Jun 19177,2489562,5990
31 Mar 19175,1519302,5690
31 Dec 18172,8661,1902,5580
30 Sep 18167,9401,6582,4600
30 Jun 18163,7631,0812,3630
31 Mar 18159,3278552,2620
31 Dec 17155,4419792,1670
30 Sep 17153,1443642,1290
30 Jun 17151,5848552,0980
31 Mar 17149,7591,1542,0890
31 Dec 16148,3101,3462,0870
30 Sep 16146,8501,4282,0910
30 Jun 16144,7591,6432,1070
31 Mar 16142,1111,5082,0930
31 Dec 15139,0823912,0160
30 Sep 15135,962-1381,9080
30 Jun 15132,080-4311,8210
31 Mar 15128,195-6581,7060
31 Dec 14123,981351,6400
30 Sep 14119,5692821,5810
30 Jun 14112,4492671,4860
31 Mar 14104,0083441,4300
31 Dec 1396,0763681,3770

Quality Earnings: C1CO34 has a large one-off loss of $881.1M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: C1CO34's current net profit margins (0.5%) are lower than last year (0.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: C1CO34's earnings have grown significantly by 30.7% per year over the past 5 years.

Accelerating Growth: C1CO34's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: C1CO34 had negative earnings growth (-13.5%) over the past year, making it difficult to compare to the Healthcare industry average (64.3%).

Return on Equity

High ROE: Whilst C1CO34's Return on Equity (193.11%) is outstanding, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 16:21
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cencora, Inc. is covered by 39 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Gregory BolanAvondale Partners
Eric ColdwellBaird